Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans

Human Molecular Genetics

Volumn 15, Issue 9, 2006, Pages 1483-1496

  Kraemer, Brian C ^a,b   Burgess, Jack K ^a,b   Chen, Jin H ^a,b   Thomas, James H ^b   Schellenberg, Gerard D ^a,b,c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEINASE; RNA; TAU PROTEIN;

ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HOMOZYGOSITY; MOLECULAR BIOLOGY; MOLECULAR CLONING; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FOLDING; RNA INTERFERENCE; RNA SEQUENCE; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; HYDROLYSIS; NERVE REGENERATION; NERVE TISSUE PROTEINS; PHENOTYPE; PROTEIN FOLDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAU PROTEINS; TRANSGENES;

ANIMALIA; CAENORHABDITIS ELEGANS;

EID: 33646133424     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddl067     Document Type: Article

References (95)

1. Ingram, E.M. and Spillantini, M.G. (2002) Tau gene mutations: Dissecting the pathogenesis of FTDP-17. Trends Mol. Med., 8, 555-562.
2. Lee, V.M.Y., Goedert, M. and Trojanowski, J.Q. (2001) Neurodegenerative tauopathies. Ann. Rev. Neurosci., 24, 1121-1159.
3. Spillantini, M.G., Bird, T.D. and Ghetti, B. (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: A new group of tauopathies. Brain Pathol., 8, 387-402.
4. Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A. et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393, 702-705.
5. Poorkaj, P., Bird, T.D., Wijsman, E., Nemens, E., Garruto, R.M., Anderson, L., Andreadis, A., Wiederholt, W.C., Raskind, M. and Schellenberg, G.D. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol., 43, 815-825.
6. Spillantini, M.G., Murrell, J.R., Goedert, M., Farlow, M.R., Klug, A. and Ghetti, B. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA, 95, 7737-7741.
7. Roy, S., Zhang, B., Lee, V.M.Y. and Trojanowski, J.Q. (2005) Axonal transport defects: A common theme in neurodegenerative diseases. Acta Neuropathol., 109, 5-13.
8. Stamer, K., Vogel, R., Thies, E., Mandelkow, E. and Mandelkow, E.M. (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol., 156, 1051-1063.
9. Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B.I., Geschwind, D.H., Bird, T.D., McKeel, D., Goate, A. et al. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science, 282, 1914-1917.
10. Goedert, M., Jakes, R. and Crowther, R.A. (1999) Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett., 450, 306-311.
11. Nacharaju, P., Lewis, J., Easson, C., Yen, S., Hackett, J., Hutton, M. and Yen, S.H. (1999) Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett., 447, 195-199.
12. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. and Hof, P.R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev., 33, 95-130.
13. Kraemer, B.C., Zhang, B., Leverenz, J.B., Thomas, J.H., Trojanowski, J.Q. and Schellenberg, G.D. (2003) Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc. Natl Acad. Sci. USA, 100, 9980-9985.
14. Iwasaki, K.K., Staunton, J., Saifee, O., Nonet, M. and Thomas, J.H. (1997) aex-3 encodes a novel regulator of presynaptic activity in C. elegans. Neuron, 18, 613-622.
15. Kamath, R.S., Fraser, A.G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M. et al. (2003) Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature, 421, 231-237.
16. Prasad, B.C., Ye, B., Zackhary, R., Schrader, K., Seydoux, G. and Reed, R.R. (1998) unc-3, a gene required for axonal guidance in Caenorhabditis elegans, encodes a member of the O/E family of transcription factors. Development, 125, 1561-1568.
17. Bloom, L. and Horvitz, H.R. (1997) The Caenorhabditis elegans gene unc-76 and its human homologs define a new gene family involved in axonal outgrowth and fasciculation. Proc. Natl Acad. Sci. USA, 94, 3414-3419.
18. Ono, S. (2001) The Caenorhabditis elegans unc-78 gene encodes a homologue of actin-interacting protein 1 required for organized assembly of muscle actin filaments. J. Cell Biol., 152, 1313-1319.
19. Waterston, R.H., Thomson, J.N. and Brenner, S. (1980) Mutants with altered muscle structure of Caenorhabditis elegans. Dev. Biol., 77, 271-302.
20. Mudher, A., Chapman, S., Richardson, J., Asuni, A., Gibb, G., Pollard, C., Killick, R., Iqbal, T., Raymond, L., Varndell, I. et al. (2001) Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J. Neurosci., 21, 4987-4995.
21. Tomizawa, K., Omori, A., Ohtake, A., Sato, K. and Takahashi, M. (2001) Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau. FEBS Lett., 492, 221-227.
22. Elyaman, W., Yardin, C. and Hugon, J. (2002) Involvement of glycogen synthase kinase-3 beta and tau phosphorylation in neuronal Golgi disassembly. J. Neurochem., 81, 870-880.
23. Godemann, R., Biernat, J., Mandelkow, E. and Mandelkow, E.M. (1999) Phosphorylation of tau protein by recombinant GSK-3 beta: Pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBS Lett., 454, 157-164.
24. Michel, G., Mercken, M., Murayama, M., Noguchi, K., Ishiguro, K., Imahori, K. and Takashima, A. (1998) Characterization of tau phosphorylation in glycogen synthase kinase-3 beta and cyclin dependent kinase-5 activator (p23) transfected cells. Biochim. Biophys. Acta, 1380, 177-182.
25. Iqbal, K., Sisodia, S.S. and Winblad, B. (2001) Alzheimer's Disease. Wiley, West Sussex, UK, pp. 609-620.
26. Sun, W., Qureshi, H.Y., Cafferty, P.W., Sobue, K., Agarwalmawal, A., Neufield, K.D. and Paudel, H.K. (2002) Glycogen synthase kinase-3 beta is complexed with tau protein in brain microtubules. J. Biol. Chem., 277, 11933-11940.
27. Wang, J.Z., Wu, Q.L., Smith, A., Grundke-Iqbal, I. and Iqbal, K. (1998) Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett., 436, 28-34.
28. Nishimura, I., Yang, Y.F. and Lu, B.W. (2004) PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell, 116, 671-682.
29. Timm, T., Li, X.Y., Biernat, J., Jiao, J., Mandelkow, E., Vandekerckhove, J. and Mandelkow, E.M. (2003) MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. EMBO J., 22, 5090-5101.
30. Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E.M. and Mandelkow, E. (1997) MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell, 89, 297-308.
31. Bernstein, H.G. and Wiederanders, B. (1994) An immunohistochemical study of cathepsin E in Alzheimer-type dementia brains. Brain Res., 667, 287-290.
32. Hellstromlindahl, E., Mousavi, M., Zhang, X., Ravid, R. and Nordberg, A. (1999) Regional distribution of nicotinic receptor subunit mRNAs in human brain: Comparison between Alzheimer and normal brain. Mol. Brain Res., 66, 94-103.
33. Teaktong, T., Graham, A., Court, J., Perry, R., Jaros, E., Johnson, M., Hall, R. and Perry, E. (2003) Alzheimer's disease is associated with a selective increase in alpha 7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia, 41, 207-211.
34. Wang, H.Y., Li, W.W., Benedetti, N.J. and Lee, D.H.S. (2003) alpha(7) nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J. Biol. Chem., 278, 31547-31553.
35. Drewes, G., Mandelkow, E.M., Baumann, K., Goris, J., Merlevede, W. and Mandelkow, E. (1993) Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett., 336, 425-432.
36. Goedert, M., Jakes, R., Qi, Z., Wang, J.H. and Cohen, P. (1995) Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J. Neurochem., 65, 2804-2807.
37. Sontag, E., Nunbhakdi-Craig, V., Lee, G., Brandt, R., Kamibayashi, C., Kuret, J., White, C.L., Mumby, M.C. and Bloom, G.S. (1999) Molecular interactions among protein phosphatase 2A, tau, and microtubules-implications for the regulation of tau phosphorylation and the development of tauopathies. J. Biol. Chem., 274, 25490-25498.
38. Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., Grover, A., DeLucia, M., McGowan, E., Lewis, J., Prihar, G. et al. (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet., 13, 703-714.
39. Shimura, H., Schwartz, D., Gygi, S.P. and Kosik, K.S. (2004) CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem., 279, 4869-4876.
40. Chirita, C.N., Congdon, E.E., Yin, H.S. and Kuret, J. (2005) Triggers of full-length tau aggregation: A role for partially folded intermediates. Biochemistry, 44, 5862-5872.
41. Liu, F., GrundkeIqbal, I., Iqbal, K. and Gong, C.X. (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci., 22, 1942-1950.
42. Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., Meyer, H.E., Mandelkow, E.M. and Mandelkow, E. (1995) Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark): A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J. Biol. Chem., 270, 7679-7688.
43. Eidenmuller, J., Fath, T., Hellwig, A., Reed, J., Sontag, E. and Brandt, R. (2000) Structural and functional implications of tau hyperphosphorylation: Information from phosphorylation-mimicking mutated tau proteins. Biochemistry, 39, 13166-13175.
44. Schneider, A., Biernat, J., Vonbergen, M., Mandelkow, E. and Mandelkow, E.M. (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry, 38, 3549-3558.
45. Biernat, J., Gustke, N., Drewes, G., Mandelkow, E.M. and Mandelkow, E. (1993) Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding. Neuron, 11, 153-163.
46. Eidenmuller, J., Fath, T., Maas, T., Pool, M., Sontag, E. and Brandt, R. (2001) Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem. J., 357, 759-767.
47. Haase, C., Stieler, J.T., Arendt, T. and Holzer, M. (2004) Pseudophosphorylation of tau protein alters its ability for self-aggregation. J. Neurochem., 88, 1509-1520.
48. Necula, M. and Kuret, J. (2005) Site-specific pseudophosphorylation modulates the rate of tau filament dissociation. FEBS Lett., 579, 1453-1457.
49. Buee-Scherrer, V., Condamines, O., Mourton-Gilles, C., Jakes, R., Goedert, M., Pau, B. and Delacourte, A. (1996) AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res. Mol. Brain Res., 39, 79-88.
50. Necula, M. and Kuret, J. (2004) Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem., 279, 49694-49703.
51. Augustinack, J.C., Schneider, A., Mandelkow, E.M. and Hyman, B.T. (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol., 103, 26-35.
52. Kopke, E., Tung, Y.C., Shaikh, S., Alonso, A.C., Iqbal, K. and Grundke-Iqbal, I. (1993) Microtubule-associated protein tau: Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem., 268, 24374-24384.
53. Ksiezak-Reding, H., Liu, W.K. and Yen, S.H. (1992) Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res., 597, 209-219.
54. Drewes, G. (2004) MARKing tau for tangles and toxicity. Trends Biochem. Sci., 29, 548-555.
55. Jiang, H., Guo, W., Liang, X. and Rao, Y. (2005) Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell, 120, 123-135.
56. Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A. and Kaibuchi, K. (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell, 120, 137-149.
57. Hernandez, F., Borrell, J., Guaza, C., Avila, J. and Lucas, J.J. (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3 beta in the brain but do not form tau filaments. J. Neurochem., 83, 1529-1533.
58. Lucas, J.L., Hernandez, F., Gomezramos, P., Moran, M.A., Hen, R. and Avila, J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3 beta conditional transgenic mice. EMBO J., 20, 27-39.
59. Brownlees, J., Irving, N.G., Brion, J.P., Gibb, B.J.M., Wagner, U., Woodgett, J. and Miller, C.C.J. (1997) Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3 beta transgenes. Neuroreport, 8, 3251-3255.
60. Li, B.L., Ryder, J., Su, Y., Moore, S.A., Liu, F., Solenberg, P., Brune, K., Fox, N., Ni, B.H., Liu, R.G. and Zhou, Y. (2004) Overexpression of GSK3 beta(S9A) resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3 beta transgenic mice. Transgenic Res., 13, 385-396.
61. Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R. and Van Leuven, F. (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol., 155, 2153-2165.
62. Nuydens, R., Van den Kieboom, G., Nolten, C., Verhulst, C., Vanosta, P., Spittaels, K., Vandenhaute, C., Defeyter, E., Geerts, H. and Van Leuven, F. (2002) Coexpression of GSK-3 beta corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau. Neurobiol. Dis., 9, 38-48.
63. Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T. et al. (2000) Glycogen synthase kinase-3 beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem., 275, 41340-41349.
64. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., Lafrancois, J., Feinstein, B. et al. (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA, 102, 6990-6995.
65. Jackson, G.R., Wiedau-Pazos, M., Sang, T.K., Wagle, N., Brown, C.A., Massachi, S. and Geschwind, D.H. (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron, 34, 509-519.
66. Mudher, A., Shepherd, D., Newman, T.A., Mildren, P., Jukes, J.P., Squire, A., Mears, A., Berg, S., MacKay, D., Asuni, A.A., Bhat, R. and Lovestone, S. (2004) GSK-3 beta inhibition reverses axonal transport defects and behavioral phenotypes in Drosophila. Mol. Psychiatry, 9, 522-530.
67. Shulman, J.M. and Feany, M.B. (2003) Genetic modifiers of tauopathy in Drosophila. Genetics, 165, 1233-1242.
68. Paschen, W. and Mengesdorf, T. (2005) Endoplasmic reticulum stress response and neurodegeneration. Cell Calcium, 38, 409-415.
69. Ballinger, C.A., Connell, P., Wu, Y., Hu, Z., Thompson, L.J., Yin, L.Y. and Patterson, C. (1999) Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell Biol., 19, 4535-4545.
70. Hatakeyama, S., Matsumoto, M., Kamura, T., Murayama, M., Chui, D.H., Planel, E., Takahashi, R., Nakayama, K.I. and Takashima, A. (2004) U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. J. Neurochem., 91, 299-307.
71. Miyasaka, T., Ding, Z., Gengyo-Ando, K., Oue, M., Yamaguchi, H., Mitani, S. and Ihara, Y. (2005) Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol. Dis., 20, 372-383.
72. Pirkkala, L., Nykanen, P. and Sistonen, L. (2001) Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J., 15, 1118-1131.
73. Davies, T.H. and Sanchez, E.R. (2005) FKBP52. Int. J. Biochem. Cell Biol., 37, 42-47.
74. Delobel, P., Leroy, O., Hamdane, M., Sambo, A.V., Delacourte, A. and Buee, L. (2005) Proteasome inhibition and tau proteolysis: An unexpected regulation. FEBS Lett., 579, 1-5.
75. Fox, R.M., Von Stetina, S.E., Barlow, S.J., Shaffer, C., Olszewski, K.L., Moore, J.H., Dupuy, D., Vidal, M. and Miller, D.M., III (2005) A gene expression fingerprint of C. elegans embryonic motor neurons. BMC Genomics, 6, 42.
76. Jones, A., Esmaeili, B. and Sattelle, D. (2004) Functional genomics of the nicotinic acetylcholine receptor family of Caenorhabditis elegans. Bioessays, 26, 39-49.
77. Doi, M. and Iwasaki, K. (2002) Regulation of retrograde signaling at neuromuscular junctions by the novel C2 domain protein AEX-1. Neuron, 33, 249-259.
78. Gieseler, K., Mariol, M.C., Bessou, C., Migaud, M., Franks, C.J., Holden-Dye, L. and Segalat, L. (2001) Molecular, genetic and physiological characterization of dystrobrevin-like (dyb-1) mutants of Caenorhabditis elegans. J. Mol. Biol., 307, 107-117.
79. Fernandez-Gonzalez, A., La Spada, A.R., Treadaway, J., Higdon, J.C., Harris, B.S., Sidman, R.L., Morgan, J.I. and Zuo, J. (2002) Purkinje cell degeneration (pcd) phenotypes caused by mutations in the axotomy-induced gene, Nna1. Science, 295, 1904-1906.
80. Nollen, E.A., Garcia, S.M., van Haaften, G., Kim, S., Chavez, A., Morimoto, R.I. and Plasterk, R.H. (2004) Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc. Natl Acad. Sci. USA, 101, 6403-6408.
81. Fernandez-Funez, P., Nino-Rosales, M.L., de Gouyon, B., She, W.C., Luchak, J.M., Martinez, P., Turiegano, E., Benito, J., Capovilla, M., Skinner, P.J. et al. (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature, 408, 101-106.
82. Kazemi-Esfarjani, P. and Benzer, S. (2000) Genetic suppression of polyglutamine toxicity in Drosophila. Science, 287, 1837-1840.
83. Willingham, S., Outeiro, T.F., DeVit, M.J., Lindquist, S.L. and Muchowski, P.J. (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science, 302, 1769-1772.
84. Asikainen, S., Vartiainen, S., Lakso, M., Nass, R. and Wong, G. (2005) Selective sensitivity of Caenorhabditis elegans neurons to RNA interference. Neuroreport, 16, 1995-1999.
85. Timmons, L., Court, D.L. and Fire, A. (2001) Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene, 263, 103-112.
86. Brenner, S. (1974) The genetics of Caenorhabditis elegans. Genetics, 77, 71-94.
87. Pekarsky, Y., Campiglio, M., Siprashvili, Z., Druck, T., Sedkov, Y., Tillib, S., Draganescu, A., Wermuth, P. and Rothman, J.H. (1998) Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc. Natl Acad. Sci. USA, 95, 8744-8749.
88. Kamath, R.S. and Ahringer, J. (2003) Genome-wide RNAi screening in Caenorhabditis elegans. Methods, 30, 313-321.
89. Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M.K., Trojanowski, J.Q. and Lee, V.M.Y. (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron, 24, 751-762.
90. Calfon, M., Zeng, H., Urano, F., Till, J.H., Hubbard, S.R., Harding, H.P., Clark, S.G. and Ron, D. (2002) IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature, 415, 92-96.
91. CGC C. elegans, Genetic Center - strain information.
92. Worm Base, http://www.wormbase.org.
93. Herman, M.A. and Horvitz, H.R. (1994) The Caenorhabditis elegans gene lin-44 controls the polarity of asymmetric cell divisions. Development, 120, 1035-1047.
94. Thomas, J.H. (1990) Genetic analysis of defecation in Caenorhabditis elegans. Genetics, 124, 855-872.
95. Tijsterman, M., Ketting, R.F., Okihara, K.L., Sijen, T. and Plasterk, R.H. (2002) RNA helicase MUT-14-dependent gene silencing triggered in C. elegans by short antisense RNAs. Science, 295, 694-697.